Akebia Therapeutics (AKBA) Non-Current Assets (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Non-Current Assets data on file, last reported at $119.0 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 11.88% year-over-year to $119.0 million in Q1 2026; TTM through Mar 2026 was $459.4 million, a 7.25% increase from a year earlier, with the FY2025 full-year figure at $123.6 million, up 15.7% from the prior year.
• Non-Current Assets for Q1 2026 stood at $119.0 million, down from $123.6 million in the prior quarter.
• Over the last five years, Non-Current Assets for AKBA reached as high as $236.7 million in Q1 2022 and fell as low as $105.8 million in Q3 2025.
• Historically, Non-Current Assets has averaged $139.8 million across 5 years, with a median of $123.6 million in 2023.
• Across the five-year window, Non-Current Assets plunged 38.97% in 2023 and climbed 15.7% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $170.9 million in 2022, then retreated by 27.69% to $123.6 million in 2023, then fell by 13.53% to $106.8 million in 2024, then rose by 15.7% to $123.6 million in 2025, then declined by 3.7% to $119.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $119.0 million in Q1 2026, $123.6 million in Q4 2025, and $105.8 million in Q3 2025.